5 Best Upside Stocks to Buy According to Analysts

In this article, we will list the 5 Best Upside Stocks to Buy According to Analysts. Please visit 9 Best Upside Stocks to Buy According to Analysts to see the extended list and the methodology behind it.

5. Praxis Precision Medicines Inc. (NASDAQ:PRAX)

Average Upside Potential: 59.90%

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best upside stocks to buy according to analysts. On April 14, Praxis Precision Medicines announced that the US FDA accepted its NDA for ulixacaltamide HCl. This treatment is intended for adults living with essential tremor/ET, a central nervous system condition. The FDA has established a Prescription Drug User Fee Act/PDUFA target action date of January 29, 2027, and currently does not anticipate holding an advisory committee meeting as part of the review process.

The application is supported by data from the Essential3 Phase 3 program, which included two pivotal studies demonstrating statistically and clinically significant results. Throughout these trials, ulixacaltamide was generally well tolerated, maintaining a safety profile consistent with earlier research and reporting no drug-related serious adverse events. This regulatory milestone follows the FDA’s decision to grant the therapy Breakthrough Therapy Designation in December 2025.

Ulixacaltamide is a selective small molecule inhibitor designed to target T-type calcium channels to block abnormal neuronal firing associated with tremor activity. As the leading program in the company’s Cerebrum small molecule platform, it represents a precision neuroscience approach to treating ET. Praxis Precision Medicines Inc. (NASDAQ:PRAX) is now focusing on the review process and preparing for a potential commercial launch to provide a therapy developed specifically for this patient population.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company engaging in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.